|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122848 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-20 01:13:29 |
|
注册时间: Date of Registration: |
2026-04-20 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
尿石症并发尿路感染的病原谱、抗菌药物耐药性及临床特征 |
|
Public title: |
Pathogen Spectrum, Antimicrobial Resistance, and Clinical Characteristics of Urolithiasis Complicated by Urinary Tract Infection |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
尿石症并发尿路感染的病原谱、抗菌药物耐药性及临床特征 |
|
Scientific title: |
Pathogen Spectrum, Antimicrobial Resistance, and Clinical Characteristics of Urolithiasis Complicated by Urinary Tract Infection |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
邹坚 |
研究负责人: |
邹坚 |
|
Applicant: |
Jian Zou |
Study leader: |
Jian Zou |
|
申请注册联系人电话: Applicant telephone: |
+86 797 588 9140 |
研究负责人电话:
Study leader's |
+86 797 588 9140 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
397441182@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
zoujian@mail.gzsrmyy.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江西省赣州市章贡区梅关大道16号赣州市人民医院检验科 |
研究负责人通讯地址: |
江西省赣州市章贡区梅关大道16号 |
|
Applicant address: |
Laboratory Department, Ganzhou People's Hospital, No. 16 Meiguan Avenue, Zhanggong District, Ganzhou |
Study leader's address: |
No. 16 Meiguan Avenue, Zhanggong District, Ganzhou |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
赣州市人民医院 |
||
|
Applicant's institution: |
Ganzhou People's Hospital |
||
|
研究负责人所在单位: |
赣州市人民医院 |
||
|
Affiliation of the Leader: |
Ganzhou People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
PJB2025-327-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
赣州市人民医院临床科研伦理分委员会 |
||
|
Name of the ethic committee: |
Research Ethics Sub-Committee of Ganzhou People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-09-17 00:00:00 | ||
|
伦理委员会联系人: |
刘文群 |
||
|
Contact Name of the ethic committee: |
Liu WenQun |
||
|
伦理委员会联系地址: |
江西省赣州市章贡区梅关大道16号 |
||
|
Contact Address of the ethic committee: |
No. 16 Meiguan Avenue, Zhanggong District, Ganzhou |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 797 588 9157 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
408488245@qq.com |
|
研究实施负责(组长)单位: |
赣州市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Ganzhou People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江西省赣州市章贡区梅关大道16号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 16 Meiguan Avenue, Zhanggong District, Ganzhou |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
研究疾病: |
尿石症并发尿路感染 |
||||||||||||||||||||||
|
Target disease: |
Urolithiasis Complicated by Urinary Tract Infection |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
分析尿石症合并尿路感染患者的病原菌分布、耐药性及其临床特点,为临床早期干预和合理用药提供科学依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To analyze the distribution and drug resistance of pathogenic bacteria as well as the clinical characteristics in patients with urolithiasis complicated by urinary tract infection, so as to provide a scientific basis for early clinical intervention and rational drug use. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄>=18,性别不限; 2.确诊尿石症并伴尿路感染; 3.中段尿培养阳性,有完整的尿培养和药敏试验结果; |
||||||||||||||||||||||
|
Inclusion criteria |
1.Inclusion criteria Age >= 18 years, sex unrestricted; 2.Confirmed diagnosis of urolithiasis complicated by urinary-tract infection; 3.Positive mid-stream urine culture with complete bacteriological and antimicrobial-susceptibility reports available; |
||||||||||||||||||||||
|
排除标准: |
1.非尿石症并伴尿路感染患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients without urolithiasis but with urinary tract infection; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-08-01 00:00:00至 To 2025-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-08-01 00:00:00 至 To 2025-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
国家生物信息中心 China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/)。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |